US FDA OKs Cadila Healthcare topicals plant

By Staff reporter

- Last updated on GMT

US FDA OKs Cadila Healthcare topicals plant
Cadila Healthcare Limited says its topical drug manufacturing plant has passed an inspection by the US Food and Drug Administration (FDA).

According to a Bombay Stock Exchange (BSE) filing​, the Cadila plant in Changodar in Ahmedabad passed an inspection conducted by the US regulator last week with no Form 483 observations.

The facility manufacturers 17 generic topical pharmaceutical products for the US market according to Cadila.

Related news

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us

Products

View more

Webinars